Lexeo Therapeutics, Inc. (LXEO) Stock Statistics & Valuation Metrics

Lexeo Therapeutics, Inc. has a market cap or net worth of $420.81M. The enterprise value is $365.70M.

Lexeo Therapeutics, Inc. has 74,087,070 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lexeo Therapeutics, Inc.’s return on equity (ROE) is -0.41 and return on invested capital (ROIC) is -42.92%.

The current PE Ratio of Lexeo Therapeutics, Inc. is ―. Lexeo Therapeutics, Inc.’s PEG ratio is 1.34.

In the last 12 months, Lexeo Therapeutics, Inc. had revenue of 0.00 and earned -99.96M in profits. Earnings per share was -1.86.

In the last 12 months, operating cash flow was -98.56M and capital expenditures -397.00K, giving a free cash flow of -98.96M billion.

Lexeo Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Lexeo Therapeutics, Inc. upcoming earnings date is May 7, 2026, Before Open (Confirmed).

Lexeo Therapeutics, Inc. as a current ratio of 11.21, with Debt / Equity ratio of 3.20%

In the past 12 months, Lexeo Therapeutics, Inc. has paid 0.00 in taxes.

Lexeo Therapeutics, Inc. EV to EBITDA ratio is -49.19, with an EV/FCF ratio of -53.27.

Lexeo Therapeutics, Inc. has $181.77M in cash and marketable securities with $7.89M in debt, giving a net cash position of $173.88M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Lexeo Therapeutics, Inc. is $19.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy